Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 3/20 | 0.50 |
| ▸ | PLD2 | O14939 | 1/20 | 0.47 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.44 |
| ▸ | RXRA | P19793 | 2/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.44 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18490953 | 0.93 | AVPR1A (0.46) | AVPR1APLD2PLD1MAPK1ALOX15 | |
| SCHEMBL3276637 | 0.90 | CALCRL (0.46) | AVPR1APLD2PLD1MAPK1ALOX15 | |
| SCHEMBL4760270 | 0.84 | F11 (0.50) | AVPR1A | |
| SCHEMBL5003859 | 0.84 | PLD2 (0.44) | AVPR1APLD2PLD1MAPTHDAC1 | |
| SCHEMBL31415673 | 0.84 | AVPR1A (0.50) | AVPR1AMAPK1ALOX15TSHRNR1H2 | |
| SCHEMBL7394064 | 0.82 | GPR119 (0.46) | MAPK1MAPTNR1H2RXRANR1H3 | |
| SCHEMBL29416284 | 0.82 | KCNH2 (0.61) | AVPR1ACALCRLKCNH2GPR119CCR5 | |
| SCHEMBL12175490 | 0.82 | HRH3 (0.52) | — | |
| SCHEMBL2102054 | 0.81 | AVPR1A (0.56) | AVPR1APLD2PLD1MAPK1ALOX15 | |
| SCHEMBL1195957 | 0.80 | NR1H2 (0.51) | MAPK1NR1H2RXRANR1H3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111848598-B | Heterocyclic compound, application thereof and composition containing same | 健艾仕生物医药有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20230099441-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | GENEROS BIOPHARMA LTD. (CN) | 2023-03-30 | — | — | US | disclosed |
| WO-2020216378-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | 健艾仕生物医药有限公司 | 2020-10-29 | — | — | WO | disclosed |
| US-10428049-B2 | TRPA1 modulators | ALGOMEDIX, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190016701-A1 | TRPA1 MODULATORS | ALGOMEDIX, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-9951046-B2 | TRPA1 modulators | ALGOMEDIX, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-8163737-B2 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163737-B2 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163737-B2 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-7834000-B2 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090176769-A1 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-20090176769-A1 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-20090176769-A1 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| EP-2065386-A1 | CGRP antagonists | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-06-03 | — | — | EP | disclosed |
| WO-2009020470-A2 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20080176843-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-07-24 | — | — | US | disclosed |
| WO-2008021375-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080004261-A1 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-03 | — | — | US | disclosed |
| US-20080004261-A1 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-03 | — | — | US | disclosed |
| US-20080004261-A1 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230099441-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | STAT5A, STAT5B, JAK2 | AVPR1A 1040/4885PLD2 2793/4885PLD1 3444/4885 |
| US-20090176769-A1 | CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, GRPR | AVPR1A 149/4885PLD2 2757/4885PLD1 3896/4885 |
| US-10428049-B2 | TRPA1 modulators | TRPA1, TRPV1, TRPV2 | AVPR1A 755/4885PLD2 829/4885PLD1 1061/4885 |
| US-20080176843-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | AVPR1A 348/4885PLD2 823/4885PLD1 1313/4885 |
| US-20190016701-A1 | TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | AVPR1A 755/4885PLD2 829/4885PLD1 1061/4885 |
| US-20080004261-A1 | CGRP receptor antagonists | CALCRL, CALCR, GRPR | AVPR1A 149/4885PLD2 2757/4885PLD1 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.